New insight into a simple high-yielding method for the production of fully folded and functional recombinant human CCL5.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 10 2024
Historique:
received: 12 07 2024
accepted: 04 10 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 15 10 2024
Statut: epublish

Résumé

Chemokines are proteins important for a range of biological processes from cell-directed migration (chemotaxis) to cell activation and differentiation. Chemokine C-C ligand 5 (CCL5) is an important pro-inflammatory chemokine attracting immune cells towards inflammatory sites through interaction with its receptors CCR1/3/5. Recombinant production of large quantities of CCL5 in Escherichia coli is challenging due to formation of inclusion bodies which necessitates refolding, often leading to low recovery of biologically active protein. To combat this, we have developed a method for CCL5 production that utilises the purification of SUMO tagged CCL5 from E. coli SHuffle cells avoiding the need to reform disulfide bonds through inclusion body purification and yields high quantities of CCL5 (~ 25 mg/L). We demonstrated that the CCL5 produced was fully functional by assessing well-established cellular changes triggered by CCL5 binding to CCR5, including receptor phosphorylation and internalisation, intracellular signalling leading to calcium flux, as well as cell migration. Overall, we demonstrate that the use of solubility tags, SHuffle cells and low pH dialysis constitutes an approach that increases purification yields of active CCL5 with low endotoxin contamination for biological studies.

Identifiants

pubmed: 39406925
doi: 10.1038/s41598-024-75327-y
pii: 10.1038/s41598-024-75327-y
doi:

Substances chimiques

Chemokine CCL5 0
CCL5 protein, human 0
Receptors, CCR5 0
Recombinant Proteins 0
CCR5 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

24188

Subventions

Organisme : UKRI: Horizon Europe Guarantee Consolidator award
ID : EP/X023680/1
Organisme : UKRI: Horizon Europe Guarantee Consolidator award
ID : EP/X023680/1
Organisme : EPSRC
ID : EP/K039660/1

Informations de copyright

© 2024. The Author(s).

Références

Scurci, I., Martins, E. & Hartley, O. CCR5: established paradigms and new frontiers for a ‘celebrity’ chemokine receptor. Cytokine 109, 81–93 (2018).
pubmed: 29903576 doi: 10.1016/j.cyto.2018.02.018
Zlotnik, A. & Yoshie, O. The chemokine superfamily revisited. Immunity. 36, 705–716 (2012).
pubmed: 22633458 pmcid: 3396424 doi: 10.1016/j.immuni.2012.05.008
Bennett, L. D. & Fox, J. M. Signoret, N. Mechanisms regulating chemokine receptor activity. Immunology 134, 246–256 (2011).
pubmed: 21977995 pmcid: 3209565 doi: 10.1111/j.1365-2567.2011.03485.x
Chan, O., Burke, J. D., Gao, D. F. & Fish, E. N. The chemokine CCL5 regulates glucose uptake and AMP kinase signaling in activated T cells to facilitate chemotaxis. J. Biol. Chem. 287, 29406–29416 (2012).
pubmed: 22782897 pmcid: 3436201 doi: 10.1074/jbc.M112.348946
Gao, D., Rahbar, R. & Fish, E. N. CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells. Open. Biol. 6, 160122 (2016).
pubmed: 27335323 pmcid: 4929946 doi: 10.1098/rsob.160122
Murooka, T. T., Rahbar, R., Platanias, L. C. & Fish, E. N. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood 111, 4892–4901 (2008).
pubmed: 18337562 pmcid: 2384123 doi: 10.1182/blood-2007-11-125039
Shaheen, Z. R. et al. CCR5 is a required signaling receptor for macrophage expression of inflammatory genes in response to viral double-stranded RNA. Am. J. Physiol. -Regul Integr. Comp. Physiol. 316, R525–R534 (2019).
pubmed: 30811246 pmcid: 6589596 doi: 10.1152/ajpregu.00019.2019
Aldinucci, D., Borghese, C. & Casagrande, N. The CCL5/CCR5 axis in cancer progression. Cancers. 12, 1765 (2020).
pubmed: 32630699 pmcid: 7407580 doi: 10.3390/cancers12071765
Zeng, Z., Lan, T., Wei, Y. & Wei, X. CCL5/CCR5 axis in human diseases and related treatments. Genes Dis. 9, 12–27 (2022).
pubmed: 34514075 doi: 10.1016/j.gendis.2021.08.004
Jiao, X. et al. Recent advances targeting CCR5 for cancer and its role in immuno-oncology. Cancer Res. 79, 4801–4807 (2019).
pubmed: 31292161 pmcid: 6810651 doi: 10.1158/0008-5472.CAN-19-1167
Marques, R. E., Guabiraba, R., Russo, R. C. & Teixeira, M. M. Targeting CCL5 in inflammation. Expert Opin. Ther. Targets. 17, 1439–1460 (2013).
pubmed: 24090198 pmcid: 7103722 doi: 10.1517/14728222.2013.837886
Fernandez, E. J. & Lolis, E. Structure function, and inhibition of chemokines. Annu. Rev. Pharmacol. Toxicol. 42, 469–499 (2002).
pubmed: 11807180 doi: 10.1146/annurev.pharmtox.42.091901.115838
Veldkamp, C. T. et al. Production of recombinant chemokines and validation of refolding. Methods Enzymol. 570, 539–565 (2016).
pubmed: 26921961 doi: 10.1016/bs.mie.2015.09.031
Picciocchi, A. et al. C-Terminal engineering of CXCL12 and CCL5 chemokines: functional characterization by electrophysiological recordings. PLOS ONE. 9, e87394 (2014).
pubmed: 24498095 pmcid: 3909184 doi: 10.1371/journal.pone.0087394
Jia, B. & Jeon, C. O. High-throughput recombinant protein expression in Escherichia coli: current status and future perspectives. Open. Biol. 6, 160196 (2016).
pubmed: 27581654 pmcid: 5008019 doi: 10.1098/rsob.160196
Cho, H. J. et al. Maltose binding protein facilitates high-level expression and functional purification of the chemokines RANTES and SDF-1α from Escherichia coli. Protein Expr Purif. 60, 37–45 (2008).
pubmed: 18455434 doi: 10.1016/j.pep.2008.03.018
Lu, Q. et al. Optimized procedures for producing biologically active chemokines. Protein Expr Purif. 65, 251–260 (2009).
pubmed: 19297698 doi: 10.1016/j.pep.2009.01.017
Lobstein, J. et al. SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. Microb. Cell. Factories. 11, 56 (2012).
doi: 10.1186/1475-2859-11-56
Giblin, S. P. et al. CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signaling. Front. Immunol. 14, 1254697 (2023).
McKenna, S. et al. A highly efficient method for the production and purification of recombinant human CXCL8. PLoS ONE 16, e0258270 (2021).
pubmed: 34653205 pmcid: 8519433 doi: 10.1371/journal.pone.0258270
Isaikina, P. et al. Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist. Sci. Adv. 7, eabg8685 (2021).
pubmed: 34134983 pmcid: 8208711 doi: 10.1126/sciadv.abg8685
Czaplewski, L. G. et al. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1α, MIP-1β, and RANTES: characterization of active disaggregated chemokine variants. J. Biol. Chem. 274, 16077–16084 (1999).
pubmed: 10347159 doi: 10.1074/jbc.274.23.16077
Abayev, M., Srivastava, G., Arshava, B., Naider, F. & Anglister, J. Detection of intermolecular transferred-NOE interactions in small and medium size protein complexes: RANTES complexed with a CCR5 N-terminal peptide. FEBS J. 284, 586–601 (2017).
pubmed: 28052516 doi: 10.1111/febs.14000
von Luettichau, I. et al. RANTES chemokine expression in diseased and normal human tissues. Cytokine. 8, 89–98 (1996).
doi: 10.1006/cyto.1996.0012
Kershaw, T., Wavre-Shapton, S. T., Signoret, N. & Marsh, M. Chapter 18 analysis of chemokine receptor endocytosis and intracellular trafficking. In Methods in Enzymology Vol. 460, 357–377 (Academic, 2009).
Mack, M. et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV Infectivity. J. Exp. Med. 187, 1215–1224 (1998).
pubmed: 9547333 pmcid: 2212227 doi: 10.1084/jem.187.8.1215
Signoret, N., Pelchen-Matthews, A., Mack, M., Proudfoot, A. E. I. & Marsh, M. Endocytosis and recycling of the HIV Coreceptor CCR5. J. Cell. Biol. 151, 1281–1294 (2000).
pubmed: 11121442 pmcid: 2190598 doi: 10.1083/jcb.151.6.1281
Signoret, N. et al. Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent. Mol. Biol. Cell. 16, 902–917 (2005).
pubmed: 15591129 pmcid: 545921 doi: 10.1091/mbc.e04-08-0687
Hickey, C. M., Wilson, N. R. & Hochstrasser, M. Function and regulation of SUMO proteases. Nat. Rev. Mol. Cell. Biol. 13, 755–766 (2012).
pubmed: 23175280 pmcid: 3668692 doi: 10.1038/nrm3478
Xu, Z. et al. Molecular basis of the redox regulation of SUMO proteases: a protective mechanism of intermolecular disulfide linkage against irreversible sulfhydryl oxidation. FASEB J. Off Publ Fed. Am. Soc. Exp. Biol. 22, 127–137 (2008).
Chen, Y. C. et al. Integrative model to coordinate the oligomerization and aggregation mechanisms of CCL5. J. Mol. Biol. 432, 1143–1157 (2020).
pubmed: 31931012 doi: 10.1016/j.jmb.2019.12.049
Lee, B. et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274, 9617–9626 (1999).
pubmed: 10092648 doi: 10.1074/jbc.274.14.9617
Flegler, A. J., Cianci, G. C. & Hope, T. J. CCR5 conformations are dynamic and modulated by localization, trafficking and G protein association. PLOS ONE 9, e89056 (2014).
pubmed: 24586501 pmcid: 3938464 doi: 10.1371/journal.pone.0089056
Wu, L. et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186, 1373–1381 (1997).
pubmed: 9334377 pmcid: 2199098 doi: 10.1084/jem.186.8.1373
Fox, J. M., Letellier, E., Oliphant, C. J. & Signoret, N. TLR2-dependent pathway of heterologous down-modulation for the CC chemokine receptors 1, 2, and 5 in human blood monocytes. Blood 117, 1851–1860 (2011).
pubmed: 21148810 doi: 10.1182/blood-2010-05-287474
Pollok-Kopp, B., Schwarze, K., Baradari, V. K. & Oppermann, M. Analysis of ligand-stimulated CC chemokine receptor 5 (CCR5) phosphorylation in Intact cells using phosphosite-specific antibodies. J. Biol. Chem. 278, 2190–2198 (2003).
pubmed: 12403770 doi: 10.1074/jbc.M209844200
Dorr, P. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721–4732 (2005).
pubmed: 16251317 pmcid: 1280117 doi: 10.1128/AAC.49.11.4721-4732.2005
Alkhatib, G., Locati, M., Kennedy, P. E., Murphy, P. M. & Berger, E. A. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology 234, 340–348 (1997).
pubmed: 9268166 doi: 10.1006/viro.1997.8673
Combadiere, C., Ahuja, S. K., Tiffany, H. L. & Murphy, P. M. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES. J. Leukoc. Biol. 60, 147–152 (1996).
pubmed: 8699119 doi: 10.1002/jlb.60.1.147
Kelly, E., Bailey, C. P. & Henderson, G. Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol. 153, S379–S388 (2008).
pubmed: 18059321 doi: 10.1038/sj.bjp.0707604
Fox, J. M., Kasprowicz, R., Hartley, O. & Signoret, N. CCR5 susceptibility to ligand-mediated down-modulation differs between human T lymphocytes and myeloid cells. J. Leukoc. Biol. 98, 59–71 (2015).
pubmed: 25957306 pmcid: 4560160 doi: 10.1189/jlb.2A0414-193RR
Singh, A., Upadhyay, V., Upadhyay, A. K., Singh, S. M. & Panda, A. K. Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process. Microb. Cell. Factories 14, 41 (2015).
doi: 10.1186/s12934-015-0222-8
Ma, Z. et al. Expression and purification of recombinant human CCL5 and its biological characterization. Protein J. 41, 337–344 (2022).
pubmed: 35524873 doi: 10.1007/s10930-022-10047-8
Boykins, R. A., Oravecz, T., Unsworth, E. & Syin, C. Chemical synthesis and characterization of chemokine RANTES and its analogues. Cytokine 11, 8–15 (1999).
pubmed: 10080874 doi: 10.1006/cyto.1998.0391
Malakhov, M. P. et al. R. SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. J. Struct. Funct. Genomics 5, 75–86 (2004).
pubmed: 15263846 doi: 10.1023/B:JSFG.0000029237.70316.52

Auteurs

Afzaal Tufail (A)

Hull York Medical School, University of York, York, YO10 5DD, UK.

Saeed Akkad (S)

Department of Chemistry, University of York, York, YO10 5DD, UK.

Amanda R Noble (AR)

Department of Chemistry, University of York, York, YO10 5DD, UK.

Martin A Fascione (MA)

Department of Chemistry, University of York, York, YO10 5DD, UK.

Nathalie Signoret (N)

Hull York Medical School, University of York, York, YO10 5DD, UK. nathalie.signoret@york.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH